Complete response of leptomeningeal carcinomatosis secondary to breast cancer

Leptomeningeal carcinomatosis (LC) is an unmet medical need associated with death in 4–6 weeks without treatment, delayed by 4 months in some patients with favorable prognosis and aggressive multimodal therapy. Unfortunately, most clinical trials excluded patients with LC, and the best management re...

Descripción completa

Detalles Bibliográficos
Autores principales: Troussier, Idriss, Canova, Charles, Klausner, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Viewpoints and Debate
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718154/
https://www.ncbi.nlm.nih.gov/pubmed/33278649
http://dx.doi.org/10.1016/j.breast.2020.11.019
Descripción
Sumario:Leptomeningeal carcinomatosis (LC) is an unmet medical need associated with death in 4–6 weeks without treatment, delayed by 4 months in some patients with favorable prognosis and aggressive multimodal therapy. Unfortunately, most clinical trials excluded patients with LC, and the best management remains unknown. Here we present the first report of a LC secondary to HR positive breast cancer with a complete response to CDK4/6 inhibitors abemaciclib, letrozole and hippocampal-avoidance whole-brain radiotherapy.

Ejemplares similares